Trial reportClinical journal of the American Society of Nephrology : CJASN2012
Vascular disease, ESRD, and death: interpreting competing risk analyses.
Trial report in Clinical journal of the American Society of Nephrology : CJASN, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 7 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Education programmes for people with chronic kidney disease and diabetes.The Cochrane database of systematic reviews · 2024Pooled it
- Low protein diets for non-diabetic adults with chronic kidney disease.The Cochrane database of systematic reviews · 2020Pooled it
- Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies.The lancet. Diabetes & endocrinology · 2019Pooled it
- Low protein diets for non-diabetic adults with chronic kidney disease.The Cochrane database of systematic reviews · 2018Pooled it
- Past Decline Versus Current eGFR and Subsequent ESRD Risk.Journal of the American Society of Nephrology : JASN · 2016Pooled it
- Pooled it
- Regression methods for investigating risk factors of chronic kidney disease outcomes: the state of the art.BMC nephrology · 2014Pooled it
- Cardiovascular outcome of glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitor on end-stage kidney disease patients with heart failure: an emulated target trial in patients with diabetes.Nature communications · 2026Observational
- Cardiovascular-Kidney-Metabolic Multimorbidity Burden and Phenotype Differentially Influence Cardiovascular and Renal Risk in Advanced Chronic Kidney Disease.Cardiorenal medicine · 2026Article
- Kidney Failure Risk Equation performance according to the etiology of chronic kidney disease in the CKD-CAREMEAU cohort.Clinical kidney journal · 2025Article
- Deprivation and chronic kidney disease-a review of the evidence.Clinical kidney journal · 2023Review
- Review
- Disease Activity and Adverse Events in Patients with ANCA-Associated Vasculitides Undergoing Long-Term Dialysis.Clinical journal of the American Society of Nephrology : CJASN · 2021Article
- Introduction to clinical research based on modern epidemiology.Clinical and experimental nephrology · 2020Review
- Helping Patients With ESRD and Earlier Stages of CKD to Quit Smoking.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2018Review
- Nationwide cohort study suggests that nucleos(t)ide analogue therapy decreases dialysis risk in Taiwanese chronic kidney disease patients acquiring hepatitis B virus infection.World journal of gastroenterology · 2018Article
- Transformation of mortality in a remote Australian Aboriginal community: a retrospective observational study.BMJ open · 2017Observational
- Tolerability of Cholinesterase Inhibitors: A Population-Based Study of Persistence, Adherence, and Switching.Drugs & aging · 2017Article
- Association between chronic kidney disease and cancer mortality: A report from the ALLHAT.Clinical nephrology · 2017Article
- Smoking, Vascular Events, and ESRD in Patients With CKD.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
objectivesVascular disease, a common condition in CKD, is a risk factor for mortality and ESRD. Optimal patient care requires accurate estimation and ordering of these competing risks. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This is a prospective cohort study of screened (n=885) and randomized participants (n=837) in the Modification of Diet in Renal Disease study (original study enrollment, 1989-1992), evaluating the association of vascular disease with ESRD and pre-ESRD mortality using standard survival analysis and competing risk regression.
resultsThe method of analysis resulted in markedly different estimates. Cumulative incidence by standard analysis (censoring at the competing event) implied that, with vascular disease, the 15-year incidence was 66% and 51% for ESRD and pre-ESRD death, respectively. A more accurate representation of absolute risk was estimated with competing risk regression: 15-year incidence was 54% and 29% for ESRD and pre-ESRD death, respectively. For the association of vascular disease with pre-ESRD death, estimates of relative risk by the two methods were similar (standard survival analysis adjusted hazard ratio, 1.63; 95% confidence interval, 1.20-2.20; competing risk regression adjusted subhazard ratio, 1.57; 95% confidence interval, 1.15-2.14). In contrast, the hazard and subhazard ratios differed substantially for other associations, such as GFR and pre-ESRD mortality.
conclusionsWhen competing events exist, absolute risk is better estimated using competing risk regression, but etiologic associations by this method must be carefully interpreted. The presence of vascular disease in CKD decreases the likelihood of survival to ESRD, independent of age and other risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.